

Press Release

New STADA facility in Romania for sustainable medicines supply in Europe

- Opening of STADA production and supply-chain hub in Turda, Romania, strengthens European security of supply with more than 150 million packs of medicines per year
- Site supports STADA's sustainability commitments, such as through ecologically-friendly packaging materials, photovoltaic solar panels and low-energy lighting
- Miguel Pagan, STADA's Chief Technical Officer: "Amid the ongoing discussions about how best to secure a sustainable supply of critical medicines in Europe, STADA is proud to make this major EU investment that will help to ensure patients can access the medicines they need."

Turda, Romania/ Bad Vilbel, Germany – 30 October 2024 – STADA has opened a major new production site and supply-chain hub in Turda, Romania, that will contribute to security of medicines supply in Europe by supplying more than 150 million packs per year. Following a total investment of more than €70 million (US\$75 million), the facility is now fully validated and approved, with initial shipments underway.

The Turda facility supports the sustainable supply of prescription medicines such as antidepressants, antihistamines and anti-inflammatory agents, as well as medicines to treat diabetes, high cholesterol levels and hypertension. Furthermore, it is shipping a wide assortment of consumer healthcare products to enable self-care from its automated warehouse that has capacity for 7,400 pallets. The 100,000 sq m greenfield site, on which construction started in late 2022¹, offers room for expansion in the future.

¹ [STADA strengthens European medicines supply | STADA](#)




By leveraging industry-leading design concepts and technologies, the production and supply-chain hub located in Cluj County reinforces STADA's commitment to sustainable medicines provision in Europe. Ecologically-friendly packaging materials are a key focus, while photovoltaic solar panels and low-energy lighting minimize carbon emissions. Already, around 45% of STADA's electricity consumption comes from renewable sources, helping STADA to rank among the top 6% of pharma companies worldwide on sustainability².

"Amid the ongoing discussions about how best to secure a sustainable supply of critical medicines in Europe, STADA is proud to make this major EU investment that will help to ensure patients can access the medicines they need," stated STADA's Chief Technical Officer, Miguel Pagan. "Having implemented industry-leading concepts in design, construction and energy conservation, the group is also playing its part in environmental sustainability."

The site in Turda's Aries Industrial Park is strategically located at the heart of STADA's European markets, and within the European Union, offering close connections and synergies with testing laboratories in Timisoara, Romania, as well as several key production facilities in the Western Balkans region and the group's consumer healthcare center of excellence in Třinec, Czech Republic.

"Working closely with national and local authorities, this state-of-the-art facility has created almost 400 jobs in Cluj County," explained Mihai Fugarevici, general manager of STADA Romania. The Turda site further enhances our capacity to deliver quality healthcare products, not only in Romania, but throughout Europe."

² [STADA reduces carbon emissions | STADA](#)



About STADA Arzneimittel AG

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in more than 100 countries. In financial year 2023, STADA achieved group revenues of EUR 3,734.8 million and reported earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 802.1 million. As of 31 December 2023, STADA employed 11,667 people worldwide.

Additional information for journalists:

STADA Arzneimittel AG - Media Relations

Stadastrasse 2-18

61118 Bad Vilbel - Germany

Phone: +49 (0) 6101 603-165

E-Mail: press@stada.de

Or visit us on the Internet at www.stada.com/press

Follow [@STADAGroup](#) on LinkedIn

Additional information for capital market participants:

STADA Arzneimittel AG - Investor & Creditor Relations

Stadastrasse 2-18

61118 Bad Vilbel – Germany

Phone: +49 (0) 6101 603-4689

Fax: +49 (0) 6101 603-215

E-mail: ir@stada.de

Or visit us on the Internet at www.stada.com/investor-relations

Executive Board: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez / Boris Döbler
Chairman of the Supervisory Board: Dr. Günter von Au